Business Wire

Zayed Sustainability Prize Demonstrates Global Reach and Impact with over 5,900 Submissions

15.7.2024 17:54:00 EEST | Business Wire | Press release

Share

The Zayed Sustainability Prize, the UAE's pioneering global award for sustainability and humanitarianism, has officially closed entries for its 2025 awards cycle. A total of 5,980 applications were received across the six Prize categories of Health, Food, Energy, Water, Climate Action and Global High Schools, from 156 countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240715270226/en/

Zayed Sustainability Prize Demonstrates Global Reach and Impact with over 5,900 Submissions (Graphic: AETOSWire)

The Zayed Sustainability Prize winners will be announced at the Awards Ceremony, which will be held on 14 January 2025 as part of Abu Dhabi Sustainability Week.

This year’s Prize has seen a notable 15% increase in submissions over the previous year from small and medium enterprises (SMEs), nonprofit organisations, and high schools. Close analysis of the submissions reveals a prevailing trend across all categories: a significant number of solutions are harnessing the power of artificial intelligence (AI), big data, blockchain, 3D printing, and biotechnology applications, revealing the importance of technological innovation in driving progress towards sustainability.

H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology, Director General of the Zayed Sustainability Prize, and COP28 President, said: “For the last 16 years, the Zayed Sustainability Prize has supported innovative solutions that address pressing global challenges and deliver tangible impact to communities around the world. Inspired by Sheikh Zayed’s commitment to humanitarianism and people focused, inclusive sustainable development, the Prize has transformed the lives of over 384 million people.”

“We are deeply encouraged by the record number of applications we have received from every continent. This overwhelming response, particularly from young people and organisations in the Global South, reinforces our belief that innovations harnessing cutting-edge technologies like artificial intelligence, coupled with community-driven approaches, are key to effectively addressing climate change and driving social and environmental progress,” he added.

This year’s submissions were more varied than ever, highlighting the universal impact of climate change on nations across all continents. Most of the submissions came from emerging markets, revealing that rapidly developing countries are at the forefront of catalysing local, innovative solutions to address the sustainability gap.

The top submitting countries included Brazil, India, Kenya, Egypt, the United Arab Emirates and the United States. This year, the Prize accepted submissions in multiple languages, including Arabic, English, French, Mandarin, Portuguese, Russian and Spanish, promoting inclusivity, ensuring broader participation, and allowing diverse perspectives from different regions and cultures to be represented.

The Food (1,255) and Climate Action (1,532) categories attracted the greatest number of submissions, followed by Health (997), Global High Schools (906), Energy (669) and Water (621).

In the Food category, which received twice as many submissions compared to last year, the entries respond to challenges related to sustainable food production through innovations like agricultural technology (Agtech) for food system resilience.

Submissions addressing deforestation and rising carbon emissions dominated the Climate Action category, with organisations leading efforts in soil restoration, biodiversity enhancement, and sustainable resource use, fostering environmental sustainability.

SMEs and NPOs in the Health category predominantly focus on enhancing access to healthcare and disease prevention through solutions that leverage innovative technologies, community-driven programmes, and partnerships to bridge gaps in medical services, especially in underserved regions.

In the Energy category, the Prize received numerous entries from organisations dedicated to expanding sustainable energy access in vulnerable communities. While submissions featuring emerging technologies like hydrogen fuel systems, energy storage solutions and electric mobility, all critical for the global energy transition, also increased significantly.

Finally, in the Water category, many entries concentrate on enhancing water accessibility through innovative solutions that emphasise water conservation, advanced recycling techniques, filtration processes, and comprehensive treatment systems to ensure clean water resources for all.

The number of submissions from high schools has more than doubled compared to the previous year, signalling a significant increase in youth involvement and dedication to sustainable practices. In the Global High Schools category, the proposals included sustainable food production methods such as hydroponics and aquaponics, effective recycling and waste management strategies, the use of bioenergy, and the creation of bioproducts.

Following the close of submissions, the Prize now enters the evaluation stage. All entries will be shortlisted by an independent research and analysis consultancy. A Selection Committee comprised of globally renowned industry experts will then assess the qualified entries and shortlist the candidates. The third and final tier of the evaluation process is the Jury, which will convene in October to unanimously elect the winners in each category.

Since its launch in 2008, the US $5.9 million Prize has transformed the lives of over 384 million people around the world. Its global impact continues to grow, as it accelerates sustainable development and humanitarian progress. Each winner in the Health, Food, Energy, Water and Climate Action categories receive US $1 million to expand the scope and scale of their sustainability solution(s), while the Global High Schools category has six winners, representing six world regions, with each winner receiving up to US $150,000.

The Zayed Sustainability Prize is the UAE’s pioneering award for innovative solutions to global challenges.

A tribute to the legacy and vision of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, the Prize aims to drive sustainable development worldwide.

Each year, across the Health, Food, Energy, Water, Climate Action and Global High Schools categories, the Prize rewards organisations and high schools for their groundbreaking solutions to our planet’s most pressing needs.

Through its 117 winners, in 16 years, the Prize has positively impacted over 384 million lives across the globe, inspiring innovators to amplify their impact, and chart a sustainable future for all.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20240715270226/en/

Contacts

Alexandra Patel, +971524407034
alexandra.patel@bursonglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye